← Back to list

VanEck Genomics and Healthcare Innovators UCITS ETF A

MVIS Global Future Healthcare ESG

Equities Sustainable (ESG)
ISIN
IE000B9PQW54
Issuer
VanEck
TER
0.35%
Latest closing price
N/A
Fund Size
€15 m As of: Sep 30, 2026
Domicile
Ireland
Distribution Policy
Accumulating
Replication Method
Physical
Base Currency
USD
WKN / Ticker
A3DSGJ / CURE

Data availability

Data is available for 2 of 5 areas for this fund.

  • Master data (TER, index, size): As of: Sep 30, 2026
  • Closing price: not available
  • Price history (at least 20 prices): not available
  • Holdings: As of: Jul 31, 2026
  • Risk figures: not available

Missing information is marked as “not available” and is not estimated. The issuer’s documents are authoritative.

At a glance

VanEck Genomics and Healthcare Innovators UCITS ETF A (ISIN IE000B9PQW54) is a fund from VanEck (fund type: ETF). Benchmark index: MVIS Global Future Healthcare ESG. Its ongoing charges (TER) are 0.35% per year. The fund size is €15 m. Distribution policy: Accumulating. Replication: Physical. Fund domicile: Ireland.

Key Facts
  • Launch date 02.09.2022 (4 years)
  • Number of Holdings 49
  • Strategy Passive (index tracking)
  • Base Currency USD
  • Currency hedging No
  • Distribution Policy Accumulating
  • Replication Method Physical
  • Securities lending No
  • Domicile IE
  • UCITS Compliant Yes

Price development

Error loading comparison.
There is not enough price data available for this period yet.

Pure price change based on stored closing prices; distributions, purchase costs and taxes are not included. Different currencies and index types (price or total return index) can distort the comparison line. Past performance is not a reliable indicator of future results.

Risk figures (12 months)

No calculated risk figures are available for this fund yet.

The official summary risk indicator (SRI, scale 1–7) is in the issuer’s key information document (KID). The figures here are historical values and do not replace it.

Documents

We have no documents stored for this fund. The key information document (KID), factsheet and prospectus are provided by the issuer.

Tracking difference and tracking error

We have no comparison series stored for this fund’s index, so a tracking analysis is not possible.

What does the fund invest in?
As of 31.07.2026 · Source: justETF / etfdb
Sector Breakdown
  • Health care 95.4%
  • Consumer staples 3.3%
  • Technology 1.3%
Country Breakdown
  • United States 82.8%
  • Germany 3.9%
  • China 3.4%
  • Netherlands 2.8%
  • Australia 2.2%
  • Switzerland 1.3%
  • Japan 1.3%
  • Sweden 1.2%
  • Other 1.2%

Holdings

Showing 10 holdings that together make up 60.8 % of fund assets. (out of 49 holdings in total).

# Name ISIN Sector Country Weight
1 Regeneron Pharmaceuticals, Inc. US75886F1075 – – 9.12 %
2 Vertex Pharmaceuticals US92532F1003 – – 7.88 %
3 Natera US6323071042 – – 7.23 %
4 DexCom US2521311074 – – 7.03 %
5 Veeva Systems US9224751084 – – 6.72 %
6 Illumina, Inc. US4523271090 – – 5.68 %
7 Guardant Health US40131M1099 – – 5.02 %
8 Moderna US60770K1079 – – 4.82 %
9 BioNTech SE US09075V1026 – – 3.85 %
10 Alnylam Pharmaceuticals US02043Q1076 – – 3.49 %
Cost calculator
What does this ETF cost you per year – and over your whole investment horizon?
Cost in year 1
–
Total cost impact
–

Simplified model based on the TER, excluding order fees, spreads, taxes and tracking difference. Not investment advice.

Alternatives on the same index
Other ETFs tracking the MVIS Global Future Healthcare ESG – cheapest first.
We know of no other ETFs tracking exactly this index.

Frequently asked questions about the VanEck Genomics and Healthcare Innovators UCITS ETF A

The total expense ratio (TER) of the VanEck Genomics and Healthcare Innovators UCITS ETF A is 0.35% per year. The costs are deducted from the fund assets on an ongoing basis and are already reflected in its performance.

The VanEck Genomics and Healthcare Innovators UCITS ETF A tracks the MVIS Global Future Healthcare ESG. Our index encyclopedia explains the index and lists all funds that track it.

The VanEck Genomics and Healthcare Innovators UCITS ETF A is accumulating: income such as dividends is not paid out but automatically reinvested in the fund.

The VanEck Genomics and Healthcare Innovators UCITS ETF A uses physical replication: it holds the securities of the index directly – either in full or as a representative sample (sampling).

The fund size of the VanEck Genomics and Healthcare Innovators UCITS ETF A is €15 m. A large fund size usually indicates good tradability and a lower risk of the fund being closed.

The VanEck Genomics and Healthcare Innovators UCITS ETF A is domiciled in Ireland. The fund domicile affects, among other things, how withholding taxes are treated inside the fund.

The provider (issuer) of the VanEck Genomics and Healthcare Innovators UCITS ETF A is VanEck.

All information without guarantee. It is provided for information purposes only and does not constitute investment advice.